Patent 11279730 was granted and assigned to SAGE Therapeutics on March, 2022 by the United States Patent and Trademark Office.
Compounds are provided according to Formula (I): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R1, R2, R3 and R6, R11a, and R11b are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.